# Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

> **NCT01737853** · — · COMPLETED · sponsor: **Allergan S.A. DE C.V..** · enrollment: 90 (actual)

## Conditions studied

- Glaucoma Primary Open Angle

## Interventions

- **DRUG:** Ganforti
- **DRUG:** Krytantek

## Key facts

- **NCT ID:** NCT01737853
- **Lead sponsor:** Allergan S.A. DE C.V..
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-02
- **Final completion:** 2012-06
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2012-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01737853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01737853, "Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01737853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*